Table 3.
Immune cell exhaustion markers selected for the final model of overall and progression-free survival using multivariate forward Cox regression.
| Tissue | Type of survival | Variable | coef | SE | HR | p-value |
|---|---|---|---|---|---|---|
| Tumor | OS | PD-L1 | 0.003 | 0.002 | 1.003 | 0.062 |
| AffLN | OS | CTLA4 | 0.003 | 0.001 | 1.003 | 0.059 |
| N1 ntbLN | OS | TIM-3 | 0.005 | 0.003 | 1.005 | 0.064 |
| PD-L1 | 0.015 | 0.007 | 1.015 | 0.031 | ||
| N2 ntbLN | OS | TIM-3 | 0.006 | 0.003 | 1.006 | 0.035 |
| Tumor | PFS | Failed to converge | ||||
| AffLN | Failed to converge | |||||
| N1 ntbLN | Failed to converge | |||||
| N2 ntbLN | Failed to converge |
HR, Hazard Ratio; LN, Lymph node; ntb, non-tumor bearing; OS, Overall survival; PFS, Progression-free survival; SE, Standard error; TIDE, Tumor Immune Evasion and Dysfunction.